Clinical effect of mesalazine combined with live bacillus licheniformis on ulcerative colitis

Chen Juan; Kang Jingdong; Wu Dongsheng

doi:10.3760/cma.j.issn.1673-4777.2016.12.015

Abstract：Objective To observe the clinical effect of mesalazine combined with live bacillus licheniformis on ulcerative colitis.Methods Totally 190 patients with ulcerative colitis from May 2014 to May 2015 in China Nuclear Industry Beijing 401 Hospital were randomly divided into observation group(96 cases) and control group(94 cases).The observation group was treated with mesalamine enteric-coated tablets and live bacillus licheniformis capsules for 12 weeks.The control group was treated with sulfasalazine tablets for 12 weeks.Symptom changes were recorded by inflammatory bowel disease life quality questionnaire(IBDQ).Colonic mucosal inflammation changes were recorded by modified Baron UC activity classification and histopathological classification.Clinical efficacy and adverse reactions were analyzed.Results After treatment,IBDQ scores in observation group and control group were significantly lower than those before treatment [(33 ± 7) scores vs (189 ± 6) scores,P =0.040;(59 ± 6) scores vs (191 ± 7) scores,P =0.049];the IBDQ score in observation group was significantly lower than that in control group(P =0.048).Colonic mucosal inflammation in observation group and control group were significantly improved(P =0.010,0.023);the inflammation condition in observation group was significantly better than that in control group after treatment(P =0.038).The observation group had a higher effective rate and a lower adverse reaction rate compared to control group;the differences were significant [87.5％ (84/96) vs 77.7％(73/94),P=0.047;1.0％(1/96) vs8.5％(8/94),P=0.041].Conclusion Mesalazine combined with live bacillus licheniformis treating ulcerative colitis is safe and effective.